“Generalized Pustular Psoriasis (GPP) Control Is Limited on Traditional Small-Molecule Therapy As Measured by the GPP Physician Global Assessment (GPPGA) and Dermatology Life Quality Index (DLQI): Baseline Data from the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine 9, no. 2 (March 17, 2025): s540. Accessed July 22, 2025. https://skin.dermsquared.com/skin/article/view/3333.